MedDataX Logo

Vitamin D Treatment in Patients With Chronic Hepatitis C

NCT ID: NCT00804752

Last Updated: 2008-12-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Study Classification

INTERVENTIONAL

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

We hypothesize that patients with Ch.HCV have a low level of vitamin D, and that by raising their vitamin D levels by adding it to their standard treament of Pegylated Interferon and Ribavirin, there will be an increase in their sustained virological response.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Hepatitis C

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Patients with Chronic Hepatitis C

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Vitamin D

An addition of Vitamin D to the standard treatment

Group Type EXPERIMENTAL

Adding vitamin D

Intervention Type DRUG

Adding 1000IU/Vitamin D daily

Vitamin D

Intervention Type DRUG

Addition of 1000IU/day Vitamin D

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Adding vitamin D

Adding 1000IU/Vitamin D daily

Intervention Type DRUG

Vitamin D

Addition of 1000IU/day Vitamin D

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Chronic Hepatitis C Genotype 1

Exclusion Criteria

* Vitamin D intoxication Renal Failure Liver Failure Malignancy
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hillel Yaffe Medical Center

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Hepatology Clinic, Hillel Yaffe Medical Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hillel Yaffe Medical Center

Hadera, , Israel

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Israel

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Saif Abu-Mouch, MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

0040-08-HYMC

Identifier Type: -

Identifier Source: org_study_id